CVAC (CureVac NV) Net Profit

Official company branding of CureVac (CVAC)

CureVac N.V. (CVAC) leverages the expertise of top German scientists to create a prestigious environment for mRNA innovation. The company is implementing automated synthesis stations to accelerate the testing of new drugs. High development costs and stringent FDA oversight, supported by EU lobbyists, create a robust moat for the business. This price chart reflects profit at the level of 0.16, confirming its status as a developer of antiviral agents.

CVAC (CureVac Pharma) Net Income history from 07/04/2022 to 01/17/2026

Analytical breakdowns and data insights for company CureVac (CVAC)

- price and consensus price forecast:
Stock Quotes CureVac Pharma|CVAC - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization CureVac Pharma|CVAC - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share CureVac|CVAC - Company Net Assets|Market Value to Book Value Ratio curevac.com|CVAC - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient CureVac N.V.|CVAC - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital CureVac NV|CVAC - Company Total Debt|Debts to Book Capitalization CureVac Pharma|CVAC - Company Long-Term Debt|Short-Term Debt Volume CureVac|Quick Liquidity Indicator curevac.com
- net income and valuation multiples indicators:
CVAC - Net Income
Summary company analysis:CureVac N.V.
Mass-produced product of CureVac NV

Fundamental profit monitoring minimizes the risks of underestimating the business's operational efficiency. For CureVac N.V. (CVAC), this is critical during the transition from pandemic-era orders to long-term oncology R&D projects. Daily net benefit calculations, reflected through the company's generated profit, capture real cash flow independently of quarterly reports. This indicator measures the actual profitability of every transaction, and its dynamics determine the fair value of capital amidst a shift in market strategy.

Main competitors

Net Income Gilead Corp|CDTX (Cidara Therapeutics Inc) - Net Profit|Net Profit novavax.com|Net Income VALN (Valneva)|VIR (Vir Biotechnology Inc) - Final Profit|SIGA Corp - Net Income|Emergent Bio - Company Net Income|Atea Pharmaceuticals - Net Profit|Net Financial Result Invivyd, Inc. IVVD|Enanta Pharmaceuticals, Inc. (ENTA) - Company Net Income|Inovio Pharmaceuticals, Inc. - Final Profit|Net Income HLVX|Net Profit Kalaris Tx|Company Net Income Dyadic International (DYAI)|Net Financial Result nanoviricides.com|Net Profit TLPH (Talphera)|COCP - Net Income|TRAW: Net Income|DWTX - Net Profit|Qualigen Therapeutics (QLGN) - Company Net Income|AlloVir - Final Profit|VBIV (VBI Vaccines, Inc.) - Net Profit|Company Net Income Virios VIRI|Net Income VXRT (Vaxart, Inc.)